Navigation Links
/C O R R E C T I O N -- Agendia B.V./
Date:6/26/2009

In the news release, "Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations" issued on 23 Jun 2009 12:00 GMT, by Agendia B.V. over PR Newswire, please be advised that the subheadline was missing from the release as incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ --

Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility

HUNTINGTON BEACH, California and AMSTERDAM, June 23 2009 - Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen's 2009 International Expert Consensus on the primary therapy of early breast cancer. The recommendations have been published online in the Annals of Oncology and will appear in the August print edition.

The St. Gallen expert panel consists of key opinion leaders from across Europe (53%), the United States (33%), and rest of the world (14%). In the recently published article highlighting the 2009 recommendations, the panellists emphasize that "in an important change from the previous St. Gallen conference...the Panel supported the use of a validated multigene- profiling assay, if readily available, as an adjunct to high-quality phenotyping of breast cancer in cases in which the indication for adjuvant chemotherapy remained uncertain."

In addition, the panel cautioned that so-called intermediate scores are not useful in clinical decision making. Currently, MammaPrint is the only breast cancer recurrence assay available that accurately yields a binary result, without an intermediate group, addressing the panel's recommendations. The FDA-cleared a
'/>"/>

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
2. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
5. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
6. Agendia Launches TargetPrint(R) for Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Research and Markets( ... "2015 Strategies in the Home/Self Testing Market" ... new 175-page report provides analysis of the major ... meters), pregnancy, ovulation, and occult blood. The report ... and competitive profiles. The growing economic ...
(Date:7/1/2015)...  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... commercialization of proprietary compounded drug formulations, today announced ... market closing bell on Thursday, July 2, 2015.  ... Go Dropless™ campaign since its launch in April ... annually in the U.S. and more than 4.3 ...
(Date:7/1/2015)... -- Lupin , Strides ... of MPP Sub-licensees to Fourteen Companies   ... rapid expansion of its network of generic manufacturers to 14 ... MPP-licensed antiretrovirals (ARVs). New companies Lupin and Strides Arcolab recently ... medicine the MPP licensed from ViiV Healthcare two months after ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3
... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: ... for diabetes therapy, and a provider of technical ... and pharmaceutical companies, today announced that, on May ... new, independent Director, Thomas B. Peter, to begin ...
... in ACR20 responses over placeboPRINCETON, N.J., May 14 ... today announced that the MDX-1100 Phase 2 proof-of-concept ... receiving methotrexate successfully met its primary endpoint. The ... randomized, double-blind, placebo-controlled Phase 2 trial indicated that ...
Cached Medicine Technology:Spherix Elects New Independent Director, and Elects Chairman of the Board 2Spherix Elects New Independent Director, and Elects Chairman of the Board 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and Families ... Trust. The grant will allow CCF to improve quality of care and save costs ... formed to respond to many changes in New York’s Medicaid system. Experts agree that ...
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... Miami, Florida (PRWEB) , ... July 01, 2015 ... ... effects for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School ... on juveniles aged 12 to 17 years who participated in the National Survey ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Franklin University, one ... Dr. Leslie King has been named Dean of the College of ... Dr. King will promote and support the vision and mission of Franklin University via ...
(Date:7/1/2015)... York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t ... fell into her lap, so too did her support of the practice; a terrible car ... , In her new book, “Do I Need It ? (And What if I ...
Breaking Medicine News(10 mins):Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... , , , ... the U.S. Food and Drug Administration (FDA) has approved a 3000 ... factor (recombinant). The new vial size offers greater convenience for ... , The 3000 IU vial may eliminate the need ...
... , NEW YORK, Aug. 7 President Bill ... Yancy, president of the American Heart Association and Dr. ... the Fourth Annual Healthy Schools Program Forum in New York to honor 114 ... to learn and staff to work. , , "As kids ...
... , ARDEE, Ireland, Aug. 7 /PRNewswire-Firstcall/ ... its results for the quarter ended June 30, 2009. Revenue in ... over the prior year quarter. The primary drivers of the increase ... and ESTRACE Cream which were partially offset by net sales declines ...
... , LOS ANGELES, Aug. 7 "August marks ... comments Susan, mother of five and teacher who recalls living with ... next you,d have thought Satan walked through the door." , ... *(Photo Caption/Cutline: Mother with drug-free daughter, a Narconon graduate.) , ...
... ... RN, MBA, CMRP, as vice president for consulting. , ... St. Louis, MO (Vocus) -- Navvis & ... consulting. Cleveland brings to the firm and its clients extensive experience and expertise in ...
... Carnegie Mellon University have developed an analytical technique ... to complex disease syndromes such as diabetes, asthma ... and molecular traits. , Rather than searching one ... a particular symptom or trait, as in ...
Cached Medicine News:Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 2Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 3Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 4Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 2Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 3Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 4Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Mother & Daughter Celebrate Victory Over 'Meth' 2Health News:Cleveland Joins Navvis & Company 2Health News:Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
For the quantitative determination of Gamma-GT in serum. Kinetic Reaction measured at 405 nm. Linearity: 600 IU/L at 37C....
Medicine Products: